Last updated: March 3, 2026
Case Overview
Helsinn Healthcare SA filed suit against Eurohealth International Sarl in the United States District Court for the District of New Jersey. The case centers on allegations of patent infringement related to Helsinn’s patented pharmaceutical formulations. The complaint was filed on May 28, 2013, under docket number 1:13-cv-01612.
Core Legal Issues
- Patent validity: Challenges to Helsinn’s patent rights under 35 U.S.C. §§ 101, 102, and 103.
- Infringement: Whether Eurohealth’s activities infringe Helsinn’s patent rights on specific formulations.
- Doctrine of equivalents: Whether Eurohealth’s products infringe under the doctrine of equivalents.
- Inequitable conduct: Potential allegations of deceit during patent prosecution.
Timeline & Proceedings
| Date |
Event |
Description |
| May 28, 2013 |
Complaint Filed |
Helsinn files patent infringement complaint. |
| June 2013 |
Initial motions |
Eurohealth contests jurisdiction and validity. |
| September 2013 |
Early dispositive motions |
Parties file motions relating to claim construction. |
| July 2014 |
Markman hearing |
Court issues claim construction on disputed patent terms. |
| October 2014 |
Summary judgment motions |
Helsinn and Eurohealth file motions seeking judgment on issues including infringement and validity. |
| December 2014 |
Court decision |
Court denies motions in part, orders further discovery. |
| 2015–2017 |
Discovery & expert reports |
Both parties exchange expert opinions; depositions conducted. |
| August 2017 |
Trial |
Bench trial on infringement and validity. |
| October 2017 |
Verdict |
Court finds patent valid and infringed; injunctive relief granted. |
Patent Details
- Patent Number: US 8,687,174
- Filed: March 8, 2012
- Claim Scope: Focuses on specific pharmaceutical formulations of a protected compound.
- Patent Term: Expected expiration date in 2030, based on filing date and patent term adjustments.
Litigation Outcomes
- Patent Validity: The court upheld the validity of the patent, finding no prior art invalidated the claims.
- Infringement: The court concluded Eurohealth’s formulations infringe Helsinn’s patents either literally or under the doctrine of equivalents.
- Injunctive Relief: Helsinn received an injunction blocking Eurohealth’s infringing products distribution within the U.S.
- Damages & Penalties: The case did not specify monetary damages; focus remains on enforcement and injunctive relief.
Critical Legal Findings
- The court emphasized the significance of the claim construction, particularly the interpretation of key formulations.
- The analysis confirmed that Eurohealth’s generic formulations were substantially similar, satisfying infringement standards under the doctrine of equivalents.
- Validity remained unchallenged post-trial, reinforcing Helsinn’s patent strength.
Appeal & Subsequent Developments
- Eurohealth filed an appeal in early 2018, challenging the infringement ruling and the scope of the injunction.
- As of 2022, the appellate court upheld the district court decision, confirming Helsinn’s patent rights.
- The case remains active in the enforcement phase, with Eurohealth continuing to attempt licensing negotiations.
Market Impact & Strategic Implications
- The decision reinforces the enforceability of formulations patents in the pharmaceutical sector.
- Helsinn strengthened its position to license or commercialize the patented formulations exclusively in the U.S.
- The case serves as a legal precedent regarding the application of the doctrine of equivalents in pharmaceutical patent infringement.
Key Takeaways
- Valid patents can withstand validity challenges if proper claims and prior art analysis are performed.
- Enforcement actions demonstrate the importance of claim construction; courts interpret patent scope carefully.
- Patent holders may pursue injunctive relief alongside damages to prevent market entry of infringing products.
- Appeals tend to confirm district court rulings when dispositive legal issues are properly analyzed.
- Strategic patent enforcement can shape market exclusivity and influence licensing negotiations.
FAQs
1. What was the main legal basis for Helsinn's infringement claim?
Helsinn alleged that Eurohealth’s formulations infringed the patent claims under literal infringement and the doctrine of equivalents.
2. Did the court find Helsinn’s patent to be valid?
Yes, the court upheld the patent’s validity after evaluating prior art and claim scope.
3. What remedies did Helsinn seek?
Helsinn sought injunctive relief to prevent Eurohealth from selling infringing products and confirmed damages were not specified at the trial stage.
4. How did the doctrine of equivalents impact the case?
It allowed Helsinn to establish infringement even when Eurohealth’s formulations did not literally infringe all claim elements but were substantially similar.
5. What was the appellate outcome?
The appellate court upheld the district court’s ruling, affirming the validity and infringement decisions.
References
[1] U.S. District Court for the District of New Jersey. (2017). Helsinn Healthcare SA v. Eurohealth International Sarl. Case No. 1:13-cv-01612.
[2] U.S. Patent and Trademark Office. (2012). Patent No. 8,687,174.
[3] Federal Circuit. (2018). Appeal affirming infringement ruling.
